Skip to content
value.today

Cure Pharmaceutical Holding Corp.

🇺🇸 Oxnard, California, USAPharmaceuticalsFounded 2014
Total raised
$13 M
2 rounds on record
Latest round
$12 M
Oct 2020
First round on record
Mar 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cure Pharmaceutical Holding Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$12 MNo. 2$10 to $50 million

Cure Pharmaceutical Holding Corp.: Raise no. 2, Oct 2020

Investors in this round

1 investor had bought by the notice of Nov 13, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$306,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mike Redard · Executive Officer
  • Robert Davidson · Executive Officer, Director
  • Anya Goldin · Director
  • Gene Salkind · Director
  • John Bell · Director
  • Josh Held · Director
  • Lauren Chung · Director
  • Nancy Duitch · Director
  • Ruben King-Shaw · Director
  • William Yuan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Axiom Capital Management, Inc. (CRD 265801) · New York, New YorkSold in CA

Remarks in the notice

  • On fees: “Placement agent fee. This amount may increase up to an additional $480,000 upon achievement of certain milestones.”
  • On the amounts: “For further explanation, please see the Current Report on Form 8-K filed by the Issuer on November 2, 2020.”

Signed by Mike Redard, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 13, 2020. Read the notice at the SEC.

debt, optionsSEC
May 2019$19 MIssued in a merger or acquisition$10 to $50 million

Cure Pharmaceutical Holding Corp.: Private sale, May 2019

Investors in this round

25 investors had bought by the notice of May 29, 2019: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Alex Katz · Executive Officer
  • Jessica Rousset · Executive Officer
  • Mark Udell · Executive Officer
  • Robert Davidson · Executive Officer, Director
  • Alan Einstein · Director
  • Charles Berman · Director
  • William Yuan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Davidson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 29, 2019. Read the notice at the SEC.

equitySEC
Mar 2018$1 MNo. 1Under $2 million

Cure Pharmaceutical Holding Corp.: Raise no. 1, Mar 2018

Investors in this round

23 investors had bought by the notice of Apr 5, 2018: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
$10,000
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Edward Maliski · Executive Officer
  • Mark Udell · Executive Officer
  • Alan Einstein · Director
  • Charles Berman · Director
  • Robert Davidson · Director · 10% cash; 7.5% warrants at 125% of price of warrants issued to investors.
  • William Yuan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Alexander Capital, L.P. (CRD 40077) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Does not include placement agent common stock purchase warrants.”

Signed by Robert Davidson, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2018. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cure Pharmaceutical Holding Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2020

That is all the official record says: Cure Pharmaceutical Holding Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cure Pharmaceutical Holding Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cure Pharmaceutical Holding Corp.
NameRoleNamed in
Mike RedardExecutive officerNov 2020
Robert DavidsonExecutive officerNov 2020
Alex KatzExecutive officerMay 2019
Jessica RoussetExecutive officerMay 2019
Mark UdellExecutive officerMay 2019
Edward MaliskiExecutive officerApr 2018
Anya GoldinDirectorNov 2020
Gene SalkindDirectorNov 2020
John BellDirectorNov 2020
Josh HeldDirectorNov 2020
Lauren ChungDirectorNov 2020
Nancy DuitchDirectorNov 2020
Robert DavidsonDirectorNov 2020
Ruben King-ShawDirectorNov 2020
William YuanDirectorNov 2020
Alan EinsteinDirectorMay 2019
Charles BermanDirectorMay 2019